89 active not recruiting. 89 Phase 1, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 89 | Active not recruiting 89 |
| Phase 2 | 30 | Active not recruiting 30 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| Study of BMS-986453 in Newly Diagnosed Multiple Myeloma BMS-986453 - Multiple Myeloma | Phase 1 | Active not recruiting | Susan Bal | 25 | 2026-02-09 | 2026-10-09 |
| A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 20 | 2025-05-13 | 2026-08-28 |
| Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant - Multiple Myeloma | Phase 1 | Active not recruiting | Washington University School of Medicine | 30 | 2025-04-04 | 2026-09-01 |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-87562761 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 17 | 2024-12-19 | 2026-11-03 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma CLN-619 - Multiple Myeloma | Phase 1 | Active not recruiting | Cullinan Therapeutics Inc. | 30 | 2024-09-03 | 2025-09-18 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig - Multiple Myeloma | Phase 1 | Active not recruiting | AbbVie | 60 | 2024-06-17 | 2026-03-27 |
| A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 108 | 2024-06-07 | 2026-11-03 |
| SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS SENTI-202 - AML/MDS, CD33 Expressing Hematological Malignancies | Phase 1 | Active not recruiting | Senti Biosciences | 21 | 2024-04-22 | 2026-02-12 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography - Multiple Myeloma | Phase 1 | Active not recruiting | City of Hope Medical Center | 15 | 2024-04-09 | 2026-11-09 |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Elranatamab, Iberdomide - Multiple Myeloma | Phase 1 | Active not recruiting | Pfizer | 100 | 2024-02-20 | 2026-09-15 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Linvoseltamab - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 148 | 2023-12-19 | 2026-11-06 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma Infusion of CS1 CAR-T cell product - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2023-07-05 | 2026-09-18 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies ABBV-101 - Hematologic Cancer | Phase 1 | Active not recruiting | AbbVie | 135 | 2023-06-09 | 2026-11-04 |
| A Rollover Study of CC-122 CC-122, Dexamethasone - Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Bristol-Myers Squibb | 12 | 2023-04-11 | 2026-11-05 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma Cevostamab, XmAb24306, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 90 | 2023-03-21 | 2026-11-09 |
Showing 20 of 89. Sign in to see all of them.
Multiple Myeloma (79) · Recurrence (15) · Lymphoma, Non-Hodgkin (9) · Waldenstrom Macroglobulinemia (9) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Large B-Cell, Diffuse (6) · Neoplasms, Plasma Cell (5) · Hematologic Neoplasms (4) · Leukemia (4) · Myelodysplastic Syndromes (4) · Neoplasms (4) · Burkitt Lymphoma (3)
Hematologic Diseases (89) · Hemic and Lymphatic Diseases (89) · Cardiovascular Diseases (88) · Hemorrhagic Disorders (88) · Vascular Diseases (88) · Blood Protein Disorders (86) · Immunoproliferative Disorders (86) · Lymphoproliferative Disorders (86) · Neoplasms by Histologic Type (86) · Paraproteinemias (86) · Immune System Diseases (85) · Neoplasms (83) · Neoplasms, Plasma Cell (82) · Pathologic Processes (25)
Dexamethasone (23) · Lenalidomide (13) · belantamab mafodotin (12) · pomalidomide (11) · Calcium Dobesilate (10) · daratumumab (10) · carfilzomib (9) · Bortezomib (7) · Cyclophosphamide (7) · auricularum (6) · dexamethasone 21-phosphate (6) · dexamethasone acetate (6) · nirogacestat (6) · fludarabine (5) · Magnetic Resonance Spectroscopy (4)
GlaxoSmithKline (8) · AbbVie (6) · Janssen Research & Development, LLC (6) · Memorial Sloan Kettering Cancer Center (6) · Mayo Clinic (4) · Baylor College of Medicine (2) · Celgene (2) · City of Hope Medical Center (2) · Genentech, Inc. (2) · Hoffmann-La Roche (2) · Massachusetts General Hospital (2) · Pfizer (2) · Poseida Therapeutics, Inc. (2) · Roswell Park Cancer Institute (2) · Abdullah Khan (1)
United States (76) · Spain (20) · France (19) · Australia (17) · Canada (17) · Germany (15) · South Korea (11) · Israel (9) · Greece (8) · Italy (8) · Netherlands (8) · Japan (7) · United Kingdom (7) · Poland (6) · Belgium (5)
Sham Mailankody, MBBS (2) · Abdullah M Khan, MBBS, MSc (1) · Alfred Garfall, MD (1) · Andrew J. Yee, MD (1) · Anupama Kumar, MD (1) · Carlos Ramos, MD (1)
PMID 34515338, PMID 20385792, PMID 23417027, PMID 25355819, PMID 25824111, PMID 27118452, PMID 27270177, PMID 32956453, PMID 33682447, PMID 33730360, PMID 33785483, PMID 34398557, PMID 35303007, PMID 35468618, PMID 35737298, PMID 36029527, PMID 36170501, PMID 36209764, PMID 37173224, PMID 37930156, PMID 38118406, PMID 38270219, PMID 38776914, PMID 39631041, PMID 39778168, PMID 39883889, PMID 40983036, PMID 41285709, PMID 41297007, PMID 41346230, PMID 41358582, PMID 42685673, PMID 42777241, PMID 42838070
2023 (18), 2019 (5), 2016 (1), 2025 (1), P30CA014089 (1), P30CA022453 (1), P30CA033572 (1), P30CA138292 (1), P50CA107399 (1), UM1CA186686 (1)